Alexis Krumme: Raising Awareness of Alloantibody Diseases in Pregnancy
Alexis Krumme, Director, Global Epidemiology, Immunology Therapy Area at Johnson & Johnson Innovative Medicine, shared a post on LinkedIn:
“This week, I’m proud to recognize High Risk Pregnancy Awareness Week and the maternal-fetal medicine and OBGYN communities working to support families facing complex pregnancies.
Alloantibody-driven diseases can cause serious, life-threatening complications for babies and pregnant individuals, but awareness and understanding remain limited.
At Johnson & Johnson Innovative Medicine, we’re proud to be advancing the field of maternal-fetal immunology, with a focus on driving awareness of hemolytic disease of the fetus and newborn (HDFN) and fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Together with the broader patient, prenatal diagnostic, and healthcare communities, we are working toward solutions that meet the real needs of individuals and their families navigating high-risk pregnancies, including those impacted by alloantibody diseases like HDFN and FNAIT.”
Stay updated with Hemostasis Today.
-
Jul 22, 2026, 06:59Martina Böhm-Weigert: Supporting Precision Dosing in Hemophilia with Fitusiran
-
Jul 22, 2026, 05:26Richard Dalyai: Can AI Safely Refill Medications?
-
Jul 22, 2026, 05:15Annie Bauzon: What Is Anemia? – Microcytic, Normocytic and Macrocytic Types Explained
-
Jul 22, 2026, 05:05Rob Maloney: What If Hemophilia No Longer Needed Lifelong Treatment?
-
Jul 22, 2026, 05:01Melina Rodriguez: First FDA-Approved VWD Prophylaxis for All Ages
-
Jul 22, 2026, 04:59Martina Wolff: Advancing Knowledge Through Global Collaboration at ISTH 2026
-
Jul 22, 2026, 04:52G. Shellye Horowitz: Hemophilia A Genetics – Hemophilia A and Pregnancy
-
Jul 21, 2026, 23:43Shadi Tabibian: The Clinical Power of Patient Stories in Rare Bleeding Disorders
-
Jul 21, 2026, 23:35Pete Stibbs: Impressed with PE Compass and Clinical Compass from Mona Ranade and Team